CoChat
Sign Up
Cited by 204CRISPR and Genetic Engineeringvaccines and immunoinformatics approachesCAR-T cell therapy research

The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.

Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes

Open access
Ferdosi, Shayesteh R., Ewaisha, Radwa, Moghadam, Farzaneh, Krishna, Sri, Park, Jin G., Ebrahimkhani, Mo R., Kiani, Samira, Anderson, Karen S.·2019·Nature Communications
DOI 10.1038/s41467-019-09693-xPMC PMC6478683

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

The CRISPR-Cas9 system has raised hopes for developing personalized gene therapies for complex diseases. Its application for genetic and epigenetic therapies in humans raises concerns over immunogenicity of the bacterially derived Cas9 protein. Here we detect antibodies to Streptococcus pyogenes Cas9 (SpCas9) in at least 5% of 143 healthy individuals. We also report pre-existing human CD8+T cell immunity in the majority of healthy individuals screened. We identify two immunodominant SpCas9 T cell epitopes for HLA-A*02:01 using an enhanced prediction algorithm that incorporates T cell receptor contact residue hydrophobicity and HLA binding and evaluated them by T cell assays using healthy donor PBMCs. In a proof-of-principle study, we demonstrate that Cas9 protein can be modified to eliminate immunodominant epitopes through targeted mutation while preserving its function and specificity. Our study highlights the problem of pre-existing immunity against CRISPR-associated nucleases and offers a potential solution to mitigate the T cell immune response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09693-x

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Detection of pre-existing B cell and T cell immune responses to SpCas9 in healthy donors and identification of two immunodominant T cell epitopes. a Specific serum Abs were detected against S. pyogenes lysate in 57.3% (n = 82) of 143 healthy controls. Sera with the highest reactivity to S. pyogenes lysate (n = 80, black circles) were screened for Abs against recombinant SpCas9, recombinant EBNA-1 protein (positive control), and human hemoglobin (negative control), of which 7 (8.8%) were positive for SpCas9 (above the dotted line; *p < 0.0001). b The top 5 predicted SpCas9 T cell epitopes and their predicted Sb and Si scores and ranking (based on the Sb.Si value)32. These top 5 peptides include the identified immunodominant (α and β; gray) and subdominant (γ and δ) epitopes that were shown to be immunogenic by IFN-γ ELISpot. c Plot of Sb and Si of predicted HLA-A*02:01 epitopes for the SpCas9 protein. Red dots represent the immunodominant and subdominant epitopes. d IFN-γ ELISpot assay of T cell reactivity of 12 healthy donors (the two non- HLA-A*02:01 are shown as open circles) to 38 predicted epitopes grouped in 10 pools, CEF (positive control peptide pool), and DMSO (negative control). Peptides α and δ were in pool 5 while β and γ were in pool 3. e IFN-γ ELISpot reactivity of healthy donor T cells (n = 12) to epitopes across the different domains of the Cas9 protein. Donors 1–10 were HLA-A*02:01, while 11 and 12 were not. Peptides α and δ overlap in 5 amino acid residues. Data represent mean ± SD. EBNA-1, Epstein-Barr virus nuclear antigen-1; Sb, normalized binding score; Si, normalized immunogenicity score. Statistical analysis was performed post hoc and results are exploratory. Source data are available in the Source Data file
Fig. 1 Detection of pre-existing B cell and T cell immune responses to SpCas9 in healthy donors and identification of two immunodominant T cell epitopes. a Specific serum Abs were detected against S. pyogenes lysate in 57.3% (n = 82) of 143 healthy controls. Sera with the highest reactivity to S. pyogenes lysate (n = 80, black circles) were screened for Abs against recombinant SpCas9, recombinant EBNA-1 protein (positive control), and human hemoglobin (negative control), of which 7 (8.8%) were positive for SpCas9 (above the dotted line; *p < 0.0001). b The top 5 predicted SpCas9 T cell epitopes and their predicted Sb and Si scores and ranking (based on the Sb.Si value)32. These top 5 peptides include the identified immunodominant (α and β; gray) and subdominant (γ and δ) epitopes that were shown to be immunogenic by IFN-γ ELISpot. c Plot of Sb and Si of predicted HLA-A*02:01 epitopes for the SpCas9 protein. Red dots represent the immunodominant and subdominant epitopes. d IFN-γ ELISpot assay of T cell reactivity of 12 healthy donors (the two non- HLA-A*02:01 are shown as open circles) to 38 predicted epitopes grouped in 10 pools, CEF (positive control peptide pool), and DMSO (negative control). Peptides α and δ were in pool 5 while β and γ were in pool 3. e IFN-γ ELISpot reactivity of healthy donor T cells (n = 12) to epitopes across the different domains of the Cas9 protein. Donors 1–10 were HLA-A*02:01, while 11 and 12 were not. Peptides α and δ overlap in 5 amino acid residues. Data represent mean ± SD. EBNA-1, Epstein-Barr virus nuclear antigen-1; Sb, normalized binding score; Si, normalized immunogenicity score. Statistical analysis was performed post hoc and results are exploratory. Source data are available in the Source Data fileCC BY · PubMed Central
Fig. 2 SpCas9 immunodominant epitope-specific CD8+T cell recognition is abolished after anchor residue mutation. a Epitope β-specific CD8+T cell response detected using β-specific pentamer in PBMCs stimulated with peptide β-pulsed antigen presenting cells. b The percentage of CD8+ pentamerβ+T cells was reduced to 0.3% when healthy donor B cell APCs were pulsed with the mutated peptide β2. c Positions, sequences, and IEDB HLA binding percentile rank of epitopes α and β before and after mutation of the anchor (2nd and/or 9th) residues. Sb, normalized binding score; Si, normalized immunogenicity score. d Representative IFN-γ ELISpot assay in triplicate wells comparing T cell reactivity to wild type or mutated epitopes α and β. These results are representative of 12 donors and two independent replicates (data from all 12 donors are shown in Supplementary Fig. 1). e, f IFN-γ ELISpot comparing T cell reactivity to APCs expressing WT or modified Cas9 proteins. APCs expressing FluM1 were used as a positive control. APCs expressing GAPDH or spiked with peptide α2 were used as negative controls. Data represent mean ± SEM of 5 replicates (right). Statistical analysis was performed post hoc and results are exploratory. Source data are available in the Source Data file
Fig. 2 SpCas9 immunodominant epitope-specific CD8+T cell recognition is abolished after anchor residue mutation. a Epitope β-specific CD8+T cell response detected using β-specific pentamer in PBMCs stimulated with peptide β-pulsed antigen presenting cells. b The percentage of CD8+ pentamerβ+T cells was reduced to 0.3% when healthy donor B cell APCs were pulsed with the mutated peptide β2. c Positions, sequences, and IEDB HLA binding percentile rank of epitopes α and β before and after mutation of the anchor (2nd and/or 9th) residues. Sb, normalized binding score; Si, normalized immunogenicity score. d Representative IFN-γ ELISpot assay in triplicate wells comparing T cell reactivity to wild type or mutated epitopes α and β. These results are representative of 12 donors and two independent replicates (data from all 12 donors are shown in Supplementary Fig. 1). e, f IFN-γ ELISpot comparing T cell reactivity to APCs expressing WT or modified Cas9 proteins. APCs expressing FluM1 were used as a positive control. APCs expressing GAPDH or spiked with peptide α2 were used as negative controls. Data represent mean ± SEM of 5 replicates (right). Statistical analysis was performed post hoc and results are exploratory. Source data are available in the Source Data fileCC BY · PubMed Central
Fig. 3 Mutated SpCas9 protein (Cas9-β2) retains its function and specificity. a 3D structure of the SpCas9 protein, showing the location of the identified immunodominant epitopes α and β. b Schematic of the experiment assessing mutagenesis capacity of Cas9-β2. Cells were transfected with either WT-Cas9, Cas9-β2, or an empty plasmid as well as 20 nt gRNA targeting EMX-1 locus. 72 h after transfection, percent cleavage was assessed by DNA extraction and illumina sequencing. c Percentage of indel formation in EMX-1 locus. Data represent mean ± SD of three individual transfections. d Schematic of the experiment assessing gRNA binding, DNA targeting and transcriptional modulation with Cas9-β2. Cells were transfected with either WT-Cas9, Cas9-β2, or an empty plasmid as well as 14nt gRNA targeting TTN or MIAT in the presence of MS2-P65-HSF1 (transcriptional modulation). 72 h after transfection, mRNA was assessed by qRT-PCR. e, f Shown is the mRNA level relative to an untransfected control experiment (n = 3 independent technical replicaes). g Mean expression levels of 24,078 protein-coding and non-coding RNA genes for WT-Cas9 and Cas9-β2 (each in duplicate) are shown. For visualization purposes, the values were transformed to a log2(CPM+1) scale. MIAT, the gRNA target gene, is highlighted in red, and R denotes Pearson correlation coefficient between two groups. Source data are available in the Source Data file
Fig. 3 Mutated SpCas9 protein (Cas9-β2) retains its function and specificity. a 3D structure of the SpCas9 protein, showing the location of the identified immunodominant epitopes α and β. b Schematic of the experiment assessing mutagenesis capacity of Cas9-β2. Cells were transfected with either WT-Cas9, Cas9-β2, or an empty plasmid as well as 20 nt gRNA targeting EMX-1 locus. 72 h after transfection, percent cleavage was assessed by DNA extraction and illumina sequencing. c Percentage of indel formation in EMX-1 locus. Data represent mean ± SD of three individual transfections. d Schematic of the experiment assessing gRNA binding, DNA targeting and transcriptional modulation with Cas9-β2. Cells were transfected with either WT-Cas9, Cas9-β2, or an empty plasmid as well as 14nt gRNA targeting TTN or MIAT in the presence of MS2-P65-HSF1 (transcriptional modulation). 72 h after transfection, mRNA was assessed by qRT-PCR. e, f Shown is the mRNA level relative to an untransfected control experiment (n = 3 independent technical replicaes). g Mean expression levels of 24,078 protein-coding and non-coding RNA genes for WT-Cas9 and Cas9-β2 (each in duplicate) are shown. For visualization purposes, the values were transformed to a log2(CPM+1) scale. MIAT, the gRNA target gene, is highlighted in red, and R denotes Pearson correlation coefficient between two groups. Source data are available in the Source Data fileCC BY · PubMed Central
Fig. 4 Immune responses to non-HLA-A*02:01 and class II epitopes of SpCas9. a Representative IFN-γ ELISpot reactivity of healthy donor T cells to non-HLA-A*02:01 SpCas9 class I epitopes (HLA-A*024:02 is shown as an example). b IFN-γ ELISpot reactivity of healthy donor MACS-sorted CD4+ T cells to SpCas9 long peptides that include epitopes in the top 2% of predicted MHC class II binders. c IFN-γ ELISpot reactivity of healthy donor CD8-depleted PBMCs stimulated with recombinant SpCas9 or EBNA proteins for 10 days. d IFN-γ ELISpot reactivity of MACS sorted CD4+ (black dots) or CD8+ (open dots) T cells isolated from PBMCs from three healthy donors unstimulated or stimulated with peptide β or CEF. Data represent mean ± SD. Source data are available in the Source Data file
Fig. 4 Immune responses to non-HLA-A*02:01 and class II epitopes of SpCas9. a Representative IFN-γ ELISpot reactivity of healthy donor T cells to non-HLA-A*02:01 SpCas9 class I epitopes (HLA-A*024:02 is shown as an example). b IFN-γ ELISpot reactivity of healthy donor MACS-sorted CD4+ T cells to SpCas9 long peptides that include epitopes in the top 2% of predicted MHC class II binders. c IFN-γ ELISpot reactivity of healthy donor CD8-depleted PBMCs stimulated with recombinant SpCas9 or EBNA proteins for 10 days. d IFN-γ ELISpot reactivity of MACS sorted CD4+ (black dots) or CD8+ (open dots) T cells isolated from PBMCs from three healthy donors unstimulated or stimulated with peptide β or CEF. Data represent mean ± SD. Source data are available in the Source Data fileCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 204

Related

See all

Metadata

Authors
Ferdosi, S. R., Ewaisha, R., Moghadam, F., Krishna, S., Park, J. G., Ebrahimkhani, M. R., Kiani, S., & Anderson, K. S.
Affiliations
  • Arizona State University (US)
  • Mayo Clinic (US)
Corresponding author
  • Kiani, Samira
  • Anderson, Karen S.
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2019-04-23
Volume
10
Issue
1
Pages
1842-1842
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-019-09693-x
PMC
PMC6478683
OpenAlex
W2950183003
Cited by
204
References
60
Citations by year
2026: 17 · 2025: 36 · 2024: 23 · 2023: 31 · 2022: 31 · 2021: 26 · 2020: 27 · 2019: 12
FWCI
7.94
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Massachusetts General Hospital
  • Defense Advanced Research Projects Agency (D16AP00047)
  • National Institute of Biomedical Imaging and Bioengineering (R01EB024562)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
CRISPR/Cas9, SpCas9, T cell epitopes, CD8+ T cell immunity, HLA-A*0201, epitope prediction, immunogenicity, gene therapy, personalized gene therapy
MeSH terms
CRISPR-Associated Protein 9, Antibodies, Bacterial, Antigen-Presenting Cells, Humans, Lymphocyte Activation, Streptococcus pyogenes, HLA-A Antigens, Genetic Therapy, Mutagenesis, CD8-Positive T-Lymphocytes, Epitope Mapping, Epitopes, T-Lymphocyte, Precision Medicine, HEK293 Cells, Cell Engineering, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review